Hologic (NASDAQ: HOLX) CEO exit tied to Blackstone, TPG buyout
Filing Impact
Filing Sentiment
Form Type
8-K
Rhea-AI Filing Summary
Hologic, Inc. announced that longtime Chairman, President and CEO Steve MacMillan will retire immediately after the closing of its go‑private merger with affiliates of funds managed by Blackstone and TPG. His departure is explicitly contingent upon, and effective as of, the transaction’s closing.
The company stated it has received all regulatory approvals necessary to complete the merger, which is expected to close on or about April 7, 2026, subject to customary conditions. Over MacMillan’s more than 12 years at Hologic, revenue increased 65%, non‑GAAP earnings per share rose 184%, the share price gained 241%, and the workforce grew by more than 1,500 employees.
Hologic’s next CEO is expected to be announced when the transaction closes. The company also reiterated forward‑looking statement cautions, highlighting risks that could still affect the merger’s completion and post‑closing outcomes, including for holders of contingent value rights (CVRs).
Positive
- None.
Negative
- None.
Insights
Hologic pairs CEO succession with final steps toward going private.
Hologic links Steve MacMillan’s retirement directly to the closing of its sale to Blackstone and TPG, signaling that leadership transition is built into the go‑private plan. All required regulatory approvals are now in hand, with closing expected around April 7, 2026, subject to remaining conditions.
MacMillan leaves after a long tenure during which revenue grew 65%, non‑GAAP EPS rose 184%, the share price increased 241%, and headcount expanded by more than 1,500. These figures frame the sale as occurring from a position of established growth rather than distress, though they are historical and not guarantees of future performance.
The company emphasizes standard forward‑looking risk factors, including potential termination of the merger agreement, closing delays, litigation, integration challenges, and variable outcomes for holders of CVRs. Actual impact on investors ultimately depends on successful closing under the existing merger terms and how post‑transaction strategy under private ownership evolves, details of which are not specified here.
8-K Event Classification
3 items: 5.02, 8.01, 9.01
3 items
Item 5.02
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers
Governance
Key personnel changes including departures, elections, or appointments of directors and executive officers.
Item 8.01
Other Events
Other
Voluntary disclosure of events the company deems important to shareholders but not covered by other items.
Item 9.01
Financial Statements and Exhibits
Exhibits
Financial statements, pro forma financial information, and exhibit attachments filed with this report.
Key Figures
Expected merger closing date: on or about April 7, 2026
Revenue growth under CEO: 65% increase
Non-GAAP EPS growth under CEO: 184% increase
+3 more
6 metrics
Expected merger closing date
on or about April 7, 2026
Go-private transaction with Blackstone and TPG
Revenue growth under CEO
65% increase
Over more than 12 years of Steve MacMillan’s tenure
Non-GAAP EPS growth under CEO
184% increase
Over more than 12 years of Steve MacMillan’s tenure
Share price performance under CEO
241% increase
Over more than 12 years of Steve MacMillan’s tenure
Workforce expansion under CEO
More than 1,500 employees
Headcount growth during Steve MacMillan’s tenure
CEO tenure length
More than 12 years
Time Steve MacMillan led Hologic
Key Terms
go-private transaction, Agreement and Plan of Merger, contingent upon, forward-looking statements, +1 more
5 terms
go-private transaction financial
"when the Company’s go-private transaction with Blackstone and TPG closes"
A go-private transaction is when a company’s publicly traded shares are bought so the business is no longer listed on a stock exchange and becomes privately owned. For investors this matters because it typically ends public trading of the stock, often pays existing shareholders a cash or stock buyout (like selling a house to a private buyer), and changes the company’s reporting, oversight and liquidity — meaning you may lose easy ways to sell your shares and face different risks and potential rewards.
Agreement and Plan of Merger regulatory
"pursuant to the Agreement and Plan of Merger, dated October 21, 2025"
An Agreement and Plan of Merger is a formal document where two companies agree to combine into one, outlining how the process will happen. It’s like a step-by-step plan for merging, and it matters because it shows both sides have agreed on the details before the official transition takes place.
contingent upon regulatory
"retirement as President and Chief Executive Officer...contingent upon, and effective as of immediately after, the closing"
forward-looking statements regulatory
"includes “forward-looking statements” within the meaning of the “safe harbor” provisions"
Forward-looking statements are predictions or plans that companies share about what they expect to happen in the future, like estimating sales or profits. They matter because they help investors understand a company's outlook, but since they are based on guesses and assumptions, they can sometimes be wrong.
contingent value rights (CVRs) financial
"the risk that the holders of the CVRs will receive less-than-anticipated payments"
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
Current Report Pursuant
to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported) April 6, 2026
(Exact Name of Registrant as Specified in Its Charter)
(State or Other Jurisdiction of Incorporation)
|
|
|
|
|
(Commission File Number)
|
(I.R.S. Employer Identification No.)
|
|
|
|
|
|
(Address of Principal Executive Offices)
|
(Zip Code)
|
(508 ) 263-2900
(Registrant’s Telephone Number, Including Area Code)
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Securities registered pursuant to Section 12(b) of the Act.
|
Title of each class
|
Trading Symbol(s)
|
Name of each exchange on which registered
|
|
|
|
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this
chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any
new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
| Item 5.02 |
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
|
On April 6, 2026, Stephen P. MacMillan informed the Board of Directors of Hologic, Inc. (the “Company”) of his retirement as President and Chief
Executive Officer and as Chairman of the Board of Directors of the Company, contingent upon, and effective as of immediately after, the closing of the acquisition of the Company by affiliates of funds managed by Blackstone Inc. and TPG Global, LLC
pursuant to the Agreement and Plan of Merger, dated October 21, 2025, by and among the Company, Hopper Parent Inc. and Hopper Merger Sub Inc (the “Merger”).
A copy of the Company’s press release announcing Mr. MacMillan’s retirement is filed with this Current Report on Form 8-K as
Exhibit 99.1.
| Item 8.01 |
Other Events.
|
On April 6, 2026, the Company announced it has received all regulatory approvals necessary to complete the Merger. The transaction is expected to
close on or about April 7, 2026, subject to the satisfaction or waiver of customary closing conditions.
Cautionary Statement Regarding Forward-Looking Statements
This Current Report on Form 8-K includes “forward-looking statements” within the meaning of the “safe harbor” provisions of the United States
Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the use of words such as “may,” “will,” “should,” “could,” “would,” “expects,” “plans,” “intends,” “anticipates,” “believes,” “estimates,” “projects,”
“predicts,” “likely,” “future,” “strategy,” “potential,” “seeks,” “goal” or other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These forward-looking statements include, but are
not limited to, statements regarding the benefits of and timeline for closing the merger. These forward-looking statements are based upon assumptions made by Hologic as of the date hereof and are subject to known and unknown risks and uncertainties
that could cause actual results to differ materially from those anticipated.
These forward-looking statements are subject to a number of risks and uncertainties that could adversely affect Hologic’s business and prospects,
and otherwise cause actual results to differ materially from those anticipated, including without limitation, the occurrence of any event, change or other circumstances that could give rise to the termination of the merger agreement entered into in
connection with the proposed transaction; the risk that the parties to the merger agreement may not be able to satisfy the conditions to the proposed transaction in a timely manner or at all; risks related to disruption of management time from
ongoing business operations due to the proposed transaction; the risk that any announcements relating to the proposed transaction could have adverse effects on the market price of Hologic’s common stock; the risk of any unexpected costs or expenses
resulting from the proposed transaction; the risk of any litigation relating to the proposed transaction; the risk that the proposed transaction and its announcement could have an adverse effect on the ability of Hologic to retain and hire key
personnel and to maintain relationships with customers, vendors, partners, employees, stockholders and other business relationships and on its operating results and business generally; and the risk that the holders of the CVRs will receive
less-than-anticipated payments with respect to the CVRs after the closing of the proposed transaction. Further information on factors that could cause actual results to differ materially from the results anticipated by the forward-looking statements
is included in the Hologic Annual Report on Form 10-K for the fiscal year ended September 27, 2025 filed with the Securities and Exchange Commission (the “SEC”) on November 18, 2025, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K and other filings made by Hologic from time to time with the SEC. These filings, when available, are
available on the investor relations section of the Hologic website at https://investors.hologic.com or on the SEC’s website at https://www.sec.gov. If any of these risks materialize or any of these assumptions prove incorrect, actual results could
differ materially from the results implied by these forward-looking statements. There may be additional risks that Hologic presently does not know of or that Hologic currently believes are immaterial that could also cause actual results to differ
from those contained in the forward-looking statements. The forward-looking statements included in this Current Report on Form 8-K are made only as of the date hereof. Hologic expressly disclaims any obligation or undertaking to release publicly any
updates or revisions to any such statements presented herein to reflect any change in expectations or any change in events, conditions or circumstances on which any such statements are based, except as required by law.
| Item 9.01 |
Financial Statements and Exhibits
|
(d) Exhibits
|
Exhibit
Number
|
Description
|
|
|
99.1
|
Press Release dated April 6, 2026.
|
|
|
104
|
Cover Page Interactive Data File (embedded within the Inline XBRL document)
|
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
|
Date: April 6, 2026
|
HOLOGIC, INC.
|
||
|
By:
|
/s/ Anne M. Liddy
|
||
|
Anne M. Liddy
|
|||
|
General Counsel
|
|||
Exhibit 99.1
Hologic Chief Executive Officer Steve MacMillan to Retire
Upon Close of Go-Private Transaction
MARLBOROUGH, Mass. (April 6, 2026) – Hologic, Inc. (Nasdaq: HOLX) announced today that Steve MacMillan, its long-time Chairman, President and Chief Executive
Officer (CEO), has decided to retire when the Company’s go-private transaction with Blackstone and TPG closes.
All required regulatory approvals have now been received for the transaction, which is expected to close on or about April 7, 2026.
“Hologic’s board of directors, and all the Company’s stakeholders, owe a debt of gratitude to Steve, one of the most respected leaders in the medical technology
industry,” said Amy Wendell, Hologic’s lead independent director. “He forged a dramatic turnaround shortly after joining the Company, led us through years of consistent growth, drove our unprecedented response to the COVID pandemic, and is guiding us
through a successful go-private transaction.”
Over MacMillan’s 12-plus years with Hologic, the Company’s revenue increased 65%, its non-GAAP earnings per share increased 184%, its share price increased
241%, and its workforce increased by more than 1,500 people.
“Leading Hologic has been the greatest honor and privilege of my career,” MacMillan said. “I’m immensely grateful to the customers and patients who trusted us,
the board and investors who supported us, and especially the employees who made all our accomplishments possible. I know they will make even greater contributions to women’s health as a private firm owned by Blackstone and TPG.”
Hologic’s next CEO is expected to be announced when the transaction closes.
MacMillan, 62, joined Hologic as President and CEO in December 2013. He was elected Chairman of the Board in 2015. From 2005 to 2012, he was President and CEO
of Stryker, where he had been president since 2003. Before that, he was a senior executive at Pharmacia and Johnson & Johnson. He began his career at Procter and Gamble in 1985. He earned a BA degree in economics from Davidson College and graduated
from Harvard Business School’s advanced management program. He has served on the boards of Davidson, Illumina (non-executive chair), AdvaMed, Alere, Boston Scientific and Texas Instruments.
About Hologic, Inc.
Hologic, Inc. is an innovative medical technology company primarily focused on improving women's health and well-being through early detection and treatment.
For more information on Hologic, visit www.hologic.com.
Hologic and associated logos are trademarks and/or registered trademarks of Hologic, Inc. and/or its subsidiaries in the United States and/or other countries.
Forward-Looking Statements
This news release includes “forward-looking statements” within the meaning of the “safe harbor” provisions of the United States Private Securities Litigation
Reform Act of 1995. Forward-looking statements may be identified by the use of words such as “may,” “will,” “should,” “could,” “would,” “expects,” “plans,” “intends,” “anticipates,” “believes,” “estimates,” “projects,” “predicts,” “likely,” “future,”
“strategy,” “potential,” “seeks,” “goal” or other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These forward-looking statements include, but are not limited to, statements
regarding the benefits of and timeline for closing the merger. These forward-looking statements are based upon assumptions made by Hologic as of the date hereof and are subject to known and unknown risks and uncertainties that could cause actual
results to differ materially from those anticipated.
These forward-looking statements are subject to a number of risks and uncertainties that could adversely affect Hologic’s business and prospects, and otherwise
cause actual results to differ materially from those anticipated, including without limitation, the occurrence of any event, change or other circumstances that could give rise to the termination of the merger agreement entered into in connection with
the proposed transaction; the risk that the parties to the merger agreement may not be able to satisfy the conditions to the proposed transaction in a timely manner or at all; risks related to disruption of management time from ongoing business
operations due to the proposed transaction; the risk that any announcements relating to the proposed transaction could have adverse effects on the market price of Hologic’s common stock; the risk of any unexpected costs or expenses resulting from the
proposed transaction; the risk of any litigation relating to the proposed transaction; the risk that the proposed transaction and its announcement could have an adverse effect on the ability of Hologic to retain and hire key personnel and to maintain
relationships with customers, vendors, partners, employees, stockholders and other business relationships and on its operating results and business generally; and the risk that the holders of the CVRs will receive less-than-anticipated payments with
respect to the CVRs after the closing of the proposed transaction. Further information on factors that could cause actual results to differ materially from the results anticipated by the forward-looking statements is included in the Hologic Annual
Report on Form 10-K for the fiscal year ended September 27, 2025 filed with the Securities and Exchange Commission (the “SEC”) on November 18, 2025, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K and other filings made by Hologic from time
to time with the SEC. These filings, when available, are available on the investor relations section of the Hologic website at https://investors.hologic.com or on the SEC’s website at https://www.sec.gov. If any of these risks materialize or any of
these assumptions prove incorrect, actual results could differ materially from the results implied by these forward-looking statements. There may be additional risks that Hologic presently does not know of or that Hologic currently believes are
immaterial that could also cause actual results to differ from those contained in the forward-looking statements. The forward-looking statements included in this news release are made only as of the date hereof. Hologic expressly disclaims any
obligation or undertaking to release publicly any updates or revisions to any such statements presented herein to reflect any change in expectations or any change in events, conditions or circumstances on which any such statements are based, except as
required by law.
Media:
Bridget Perry
Senior Director, Corporate Communications
(+1) 508.263.8654
bridget.perry@hologic.com
Investors:
Michael Watts
Corporate Vice President, Investor Relations
(+1) 858.410.8514
michael.watts@hologic.com
Source: Hologic, Inc.
FAQ
What did Hologic (HOLX) announce about its CEO in this 8-K?
Hologic announced that CEO and Chairman Steve MacMillan will retire immediately after its go-private merger with Blackstone and TPG closes. His departure is contingent on the transaction’s completion, aligning leadership succession with the company’s transition to private ownership.
When is Hologic’s go-private transaction with Blackstone and TPG expected to close?
Hologic stated that all required regulatory approvals have been received and the go-private transaction is expected to close on or about April 7, 2026. Completion still depends on the satisfaction or waiver of customary closing conditions in the merger agreement.
How is Steve MacMillan’s retirement tied to Hologic’s merger?
Steve MacMillan’s retirement as President, CEO and Chairman is contingent upon, and effective immediately after, the closing of Hologic’s merger with Blackstone- and TPG-affiliated entities. This links the leadership change directly to the company’s planned transition to private ownership.
What performance metrics did Hologic highlight from MacMillan’s tenure?
Hologic noted that over MacMillan’s more than 12 years, revenue grew 65%, non-GAAP earnings per share rose 184%, the share price increased 241%, and the workforce expanded by more than 1,500 employees. These data points underscore substantial long-term growth under his leadership.
Has Hologic received all regulatory approvals for the merger with Blackstone and TPG?
Yes. Hologic disclosed that it has received all regulatory approvals needed to complete the merger with affiliates of funds managed by Blackstone and TPG. The transaction is now expected to close on or about April 7, 2026, pending remaining customary closing conditions.
What risks and forward-looking factors did Hologic emphasize about the merger?
Hologic cited risks such as potential termination of the merger agreement, failure to satisfy closing conditions, litigation, integration challenges, and possible adverse effects on relationships and CVR payments. These factors could cause actual outcomes to differ materially from current expectations.